Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | USP8 | P40818 | 2/20 | 0.36 |
| ▸ | USP7 | Q93009 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18307747 | 0.86 | GRM2 (0.43) | ARUSP8USP7PDE3BPDE3A | |
| SCHEMBL17031796 | 0.84 | CA1 (0.40) | ARUSP8USP7PDE3BPDE3A | |
| SCHEMBL17033163 | 0.81 | TSHR (0.42) | ARUSP8USP7GABRA1GABRG2 | |
| SCHEMBL17031806 | 0.81 | AKR1C3 (0.39) | PDE3BPDE3AALDH1A1NPC1PLA2G1B | |
| SCHEMBL18308907 | 0.80 | FABP1 (0.40) | PDE3BPDE3AALDH1A1NPC1PLA2G1B | |
| SCHEMBL19091564 | 0.79 | AR (0.40) | ARUSP8USP7GABRA1GABRG2 | |
| SCHEMBL21022649 | 0.77 | ESR2 (0.44) | ARUSP8USP7GABRA1GABRG2 | |
| SCHEMBL17031822 | 0.76 | RAB9A (0.34) | ALDH1A1NPC1PLA2G1BNFKB1CASP3 | |
| SCHEMBL17031801 | 0.76 | BRD4 (0.39) | PGRALDH1A1NPC1RAB9AKDM4E | |
| SCHEMBL21116203 | 0.74 | USP8 (0.42) | USP8USP7GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200062790-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-27 | — | — | US | disclosed |
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428095-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10253053-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190048033-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550140-B2 | Ether compounds for treatment of complement mediated disorders | TFPI, CFD, C9 | AR 3458/4885USP8 4148/4885USP7 4548/4885 |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | AR 3367/4885USP8 3598/4885USP7 4316/4885 |
| US-20150239868-A1 | Alkyne Compounds for Treatment of Complement Mediated Disorders | CFD, C9, TFPI | AR 3601/4885USP8 4731/4885USP7 4583/4885 |
| US-10428095-B2 | Compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | AR 4543/4885USP8 4744/4885USP7 4677/4885 |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | AR 4543/4885USP8 4744/4885USP7 4677/4885 |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | AR 4141/4885USP8 4717/4885USP7 4760/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | AR 4708/4885USP8 4559/4885USP7 4527/4885 |
| US-10253053-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | TFPI, CFD, F3 | AR 3476/4885USP8 4569/4885USP7 4748/4885 |
| US-20200062790-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, F3 | AR 3476/4885USP8 4569/4885USP7 4748/4885 |
| US-20190048033-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | AR 3458/4885USP8 4148/4885USP7 4548/4885 |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | AR 4562/4885USP8 4806/4885USP7 4811/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | AR 4141/4885USP8 4717/4885USP7 4760/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | AR 3458/4885USP8 4148/4885USP7 4548/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | AR 4016/4885USP8 4628/4885USP7 4770/4885 |
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | AR 3476/4885USP8 4569/4885USP7 4748/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | AR 4016/4885USP8 4628/4885USP7 4770/4885 |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | AR 4562/4885USP8 4806/4885USP7 4811/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | AR 4141/4885USP8 4717/4885USP7 4760/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | AR 4562/4885USP8 4806/4885USP7 4811/4885 |
| US-20150239919-A1 | Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders | CFD, C9, CFH | AR 4334/4885USP8 4089/4885USP7 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.